Remember Martin Shkreli? I wrote about him some months ago. Shkreli’s securities fraud trial started last week. He became the poster child for all that is wrong with the pharmaceutical industry when he raised the price of a common drug used to treat newborns and HIV patients from $13.50 to $750 per pill. Among other things, Shkreli created two hedge funds and Retrophin, a biopharmaceutical company.  Shkreli told investors he had a successful track record as a hedge fund manager. That was probably true. Shkreli had been on Wall Street since he turned 17 years old and was, for a … Continue reading Prosecuting Ponzi Schemes: What We Can Learn From Martin Shkreli’s Trial